The link between chronic fatigue syndrome and gut dysbiosis
Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis, is a complex condition characterized by debilitating fatigue that does not improve with rest and worsens with physical or mental activity. In recent years, numerous researches have shown a significant correlation between alterations in the gut microbiota and the development of this condition.
Dysbiosis and intestinal permeability
Studies have found that patients with CFS have a reduced diversity of gut microbiota, characterized by a decrease in beneficial bacteria such as Bifidobacteria and Lactobacillus, in the face of an increase in pro-inflammatory bacterial species【13†source】【14†source】. This imbalance promotes systemic inflammation, facilitated by intestinal permeability (“Leaky Gut Syndrome”), which allows toxins and pathogenic bacteria to pass into the bloodstream. Once in the bloodstream, these substances activate a chronic immune response, resulting in the release of IgA and IgM against the lipopolysaccharide (LPS) of gram-negative bacteria【15†source】. This process has been related not only to inflammation but also to an exacerbation of systemic symptoms of CFS, including chronic fatigue, muscle pain, and cognitive difficulties.
Systemic inflammation and immune response
Chronic intestinal inflammation and the resulting systemic immune response are considered among the main pathogenic mechanisms of CFS. Gut permeability induces the transit of pathogenic bacteria into the bloodstream, which increases the body's immune load, exacerbating symptoms related to chronic fatigue. The presence of elevated levels of C-reactive protein (CRP) and other inflammatory cytokines in CFS patients confirms their systemic inflammation【16†source】【15†source】.
Microbiota-based therapeutic strategies
Given the central role of the microbiota in CFS, therapeutic strategies aimed at rebalancing the gut microbiota are being developed. Supplementation with probiotics and prebiotics, along with dietary modifications to promote beneficial bacteria and reduce intestinal inflammation, has shown therapeutic potential. Dietary interventions may reduce intestinal permeability and modulate inflammation, helping to improve CFS symptoms. Ongoing studies also evaluate the efficacy of fecal microbiota transplantation (FMT) as a potential therapeutic option【14†source】【16†source】.
For physicians and specialists, it is crucial to recognize gut dysbiosis as a possible pathogenic component in CFS. Proposing an assessment of the gut microbiota in patients with symptoms of chronic fatigue, post-exercise fatigue, muscle pain, and systemic inflammation could prove useful in improving disease management. Specific tests that analyze the composition of the microbiota, together with the measurement of inflammatory biomarkers, may provide a more complete diagnostic picture and guide targeted interventions.
Primary sources:
- Cornell University【13†source】 study.
- European Journal of Medical Research【14†fonte】- Nutrition & Metabolism【16†fonte】
